Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of stage III melanoma in patients with BRAF V600 mutations in clinical trials. However, little is known about how these therapies compare to each other in everyday practice. The aim of our study was to describe the toxicity and survival of patients treated with BRAF/MEK therapy and anti-PD-1 therapy in daily practice. We demonstrated that grade >= 3 toxicity occurred in 11.5% of patients and was the most common cause of early treatment discontinuation (71.1%). We also show that at 12 months, patients treated with BRAF/MEK therapy have less progression than those treated with anti-PD-1 therapy. However, this is no longer the case at 18 months....
BackgroundProgrammed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvan...
Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PF...
International audienceDespite significant progress in melanoma survival, therapeutic options are sti...
Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of ...
BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy...
Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RF...
Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy...
BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant ...
Background: PD-1 antibodies and BRAF+MEK inhibitors are widely used for adjuvant therapy of fully re...
Summary Background Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved ...
BackgroundProgrammed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvan...
Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PF...
International audienceDespite significant progress in melanoma survival, therapeutic options are sti...
Simple Summary BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival of ...
BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy...
Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RF...
Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy...
BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant ...
Background: PD-1 antibodies and BRAF+MEK inhibitors are widely used for adjuvant therapy of fully re...
Summary Background Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved ...
BackgroundProgrammed death-1 (PD-1) antibodies and BRAF + MEK inhibitors are widely used for adjuvan...
Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PF...
International audienceDespite significant progress in melanoma survival, therapeutic options are sti...